查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1544103

全球臨床前影像市場（In-VIVO）

Preclinical Imaging (In-VIVO)
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球臨床前影像 (In-VIVO) 市場預計將達到 14 億美元

全球臨床前影像 (In-VIVO) 市場預計 2023 年將達到 10 億美元，預計到 2030 年將達到 14 億美元，在 2023-2030 年分析期間複合年成長率為 4.8%。臨床前影像模式是本報告分析的細分市場之一，預計複合年成長率為 5.2%，到分析期結束時將達到 9.01 億美元。分析期間，臨床前成像試劑領域的複合年成長率預計為 4.2%。

美國市場預估為2.787億美元，中國預期複合年成長率為4.6%

預計 2023 年美國臨床前影像 (In-VIVO) 市場規模將達到 2.787 億美元。中國作為全球第二大經濟體，預計2030年市場規模將達2.252億美元，2023年至2030年複合年成長率為4.6%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 4.6% 和 3.8%。在歐洲，德國的複合年成長率預計為 4.1%。

全球臨床前影像（體內）市場 - 主要趨勢與促進因素總結

臨床前影像（In-VIVO）：生物醫學研究的進展

臨床前成像（In-VIVO）是指使用先進​​的成像技術來視覺化和研究活體動物模型中的生物過程，主要用於生物醫學研究目的。這種診斷影像在人體臨床試驗之前進行，有助於研究人員了解疾病機制、評估新藥的有效性並即時監測治療效果。臨床前研究中常用的影像方法包括磁振造影（MRI）、正子斷層掃描（PET）、電腦斷層掃描（CT）以及生物發光和螢光成像等光學成像技術。臨床前影像的重要性在於提供對健康和疾病背後的生物過程的詳細了解，使研究人員能夠在藥物開發和生物醫學研究的其他領域做出明智的決定。臨床前影像可以對疾病進展和治療效果進行非侵入性監測，在醫學進步中發揮重要作用。

科技進步如何改善臨床前影像（體內）？

技術進步顯著提高了臨床前成像能力，提高了顯像模式的解析度和能力。高場 MRI 磁體和高靈敏度 PET檢測器等成像硬體的創新提高了影像的空間和時間解析度，使生物過程能夠更詳細地可視化。結合兩種或多種成像技術（例如 PET/CT 和 MRI/PET）的多模態影像系統的發展，使研究人員能夠同時獲得互補的資料，從而更全面地了解疾病機制和治療效果。分子造影劑（包括靶向顯影劑和放射性示踪劑）的進步提高了成像的特異性，並使特定分子途徑和細胞過程的可視化成為可能。此外，透過將人工智慧（AI）和機器學習演算法整合到影像分析中，提高了處理和解釋複雜影像資料的能力，從而產生更準確和高效的研究結果。這些技術進步擴大了臨床前影像的範圍和影響，使其成為生物醫學研究的重要工具。

臨床前影像（In-VIVO）的主要用途和優點是什麼？

臨床前影像 (In-VIVO) 用於各種研究領域，並提供許多好處，可促進疾病了解和新治療方法的開發。在腫瘤學研究中，臨床前影像可以對腫瘤生長和轉移進行非侵入性追蹤，幫助研究人員即時評估癌症治療的有效性。在神經科學領域，MRI 和 PET 等影像技術用於研究大腦結構和功能，從而深入了解阿茲海默症和帕金森氏症等神經系統疾病。心血管研究受益於臨床前成像，透過可視化心臟和血管功能，這有助於心臟病研究和新心血管藥物的開發。此外，臨床前影像也用於藥物動力學和動態研究，以監測藥物在體內的分佈和作用。臨床前影像的主要優點包括能夠非侵入性地即時監測生物過程、透過縱向研究減少動物的使用以及產生對臨床研究有用的高解析度資料。這些優勢使臨床前成像成為現代生物醫學研究的重要組成部分。

推動臨床前影像（體內）市場成長的因素有哪些？

臨床前成像（In-VIVO）市場的成長受到多種因素的推動。由於臨床前影像為臨床研究和藥物開發提供了重要訊息，因此對更準確和非侵入性方法來研究疾病機制和評估藥物療效的需求不斷成長。此外，提高成像模式的解析度、靈敏度和功能的技術進步也在推動市場成長。製藥和生物技術產業的擴張，特別是個人化醫療領域的擴張，導致對臨床前影像工具的需求增加。此外，人們越來越關注減少研究中動物的使用，再加上臨床前成像能夠對同一動物進行長期研究，這進一步推動了市場滲透。包括人工智慧和機器學習在內的先進資料分析技術的整合正在提高臨床前成像的效用並推動其持續成長。這些因素加上成像技術的不斷創新，正在推動臨床前影像（In-VIVO）市場的持續成長。

受訪企業範例（共38家）

  • Aspect Imaging Ltd.
  • Bruker Corp.
  • Idex Health & Science LLC
  • Mauna Kea Technologies
  • Mediso Ltd.
  • Milabs BV
  • Miltenyi Biotech GmbH
  • MR Solutions
  • New England Biolabs
  • PerkinElmer, Inc.
  • Siemens AG
  • Trifoil Imaging, Inc.
  • FujiFilm VisualSonics, Inc.

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他領域

第4章 比賽

簡介目錄
Product Code: MCP14177

Global Preclinical Imaging (In-VIVO) Market to Reach US$1.4 Billion by 2030

The global market for Preclinical Imaging (In-VIVO) estimated at US$1.0 Billion in the year 2023, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2023-2030. Preclinical Imaging Modalities, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$900.1 Million by the end of the analysis period. Growth in the Preclinical Imaging Reagents segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$278.7 Million While China is Forecast to Grow at 4.6% CAGR

The Preclinical Imaging (In-VIVO) market in the U.S. is estimated at US$278.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$225.2 Million by the year 2030 trailing a CAGR of 4.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 3.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Preclinical Imaging (In-VIVO) Market - Key Trends and Drivers Summarized

Preclinical Imaging (In-VIVO): Advancing Biomedical Research

Preclinical imaging (in-vivo) refers to the use of advanced imaging techniques to visualize and study biological processes in live animal models, primarily for biomedical research purposes. This imaging is conducted before clinical trials in humans, helping researchers understand disease mechanisms, evaluate the efficacy of new drugs, and monitor treatment effects in real-time. Common imaging modalities used in preclinical research include magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), and optical imaging techniques such as bioluminescence and fluorescence imaging. The importance of preclinical imaging lies in its ability to provide detailed insights into the biological processes underlying health and disease, enabling researchers to make informed decisions in drug development and other areas of biomedical research. By allowing non-invasive monitoring of disease progression and treatment response, preclinical imaging plays a crucial role in the advancement of medical science.

How Are Technological Advancements Enhancing Preclinical Imaging (In-VIVO)?

Technological advancements have significantly improved the capabilities of preclinical imaging, enhancing both the resolution and functionality of imaging modalities. Innovations in imaging hardware, such as higher-field MRI magnets and more sensitive PET detectors, have increased the spatial and temporal resolution of images, allowing for more detailed visualization of biological processes. The development of multimodal imaging systems, which combine two or more imaging techniques (e.g., PET/CT or MRI/PET), has enabled researchers to simultaneously capture complementary data, providing a more comprehensive understanding of disease mechanisms and treatment effects. Advances in molecular imaging agents, including targeted contrast agents and radiotracers, have improved the specificity of imaging, allowing for the visualization of specific molecular pathways and cellular processes. Additionally, the integration of artificial intelligence (AI) and machine learning algorithms into image analysis has enhanced the ability to process and interpret complex imaging data, facilitating more accurate and efficient research outcomes. These technological improvements have expanded the applications and impact of preclinical imaging, making it an indispensable tool in biomedical research.

What Are the Key Applications and Benefits of Preclinical Imaging (In-VIVO)?

Preclinical imaging (in-vivo) is used in various research areas, offering numerous benefits that advance the understanding of disease and the development of new treatments. In oncology research, preclinical imaging allows for the non-invasive tracking of tumor growth and metastasis, helping researchers evaluate the effectiveness of cancer therapies in real-time. In neuroscience, imaging techniques such as MRI and PET are used to study brain structure and function, providing insights into neurological disorders such as Alzheimer's disease and Parkinson's disease. Cardiovascular research benefits from preclinical imaging through the visualization of heart and blood vessel function, aiding in the study of heart disease and the development of new cardiovascular drugs. Additionally, preclinical imaging is used in pharmacokinetics and pharmacodynamics studies to monitor the distribution and action of drugs within the body. The primary benefits of preclinical imaging include the ability to conduct non-invasive, real-time monitoring of biological processes, the reduction of animal use through longitudinal studies, and the generation of high-resolution data that can inform clinical research. These advantages make preclinical imaging a critical component of modern biomedical research.

What Factors Are Driving the Growth in the Preclinical Imaging (In-VIVO) Market?

The growth in the preclinical imaging (in-vivo) market is driven by several factors. The increasing demand for more precise and non-invasive methods to study disease mechanisms and evaluate drug efficacy is a significant driver, as preclinical imaging provides critical insights that inform clinical research and drug development. Technological advancements that enhance the resolution, sensitivity, and functionality of imaging modalities are also propelling market growth. The expansion of the pharmaceutical and biotechnology industries, particularly in the area of personalized medicine, is contributing to the increased demand for preclinical imaging tools. Additionally, the growing emphasis on reducing animal use in research, coupled with the ability of preclinical imaging to enable longitudinal studies in the same animals, is further boosting market adoption. The integration of advanced data analysis techniques, including AI and machine learning, is enhancing the utility of preclinical imaging, driving its continued growth. These factors, combined with the ongoing innovation in imaging technologies, are driving the sustained growth of the preclinical imaging (in-vivo) market.

Select Competitors (Total 38 Featured) -

  • Aspect Imaging Ltd.
  • Bruker Corp.
  • Idex Health & Science LLC
  • Mauna Kea Technologies
  • Mediso Ltd.
  • Milabs B.V.
  • Miltenyi Biotech GmbH
  • MR Solutions
  • New England Biolabs
  • PerkinElmer, Inc.
  • Siemens A.G.
  • Trifoil Imaging, Inc.
  • FujiFilm VisualSonics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Preclinical Imaging (In-VIVO) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Technological Advancements in Imaging Modalities Propel Market Growth
    • Rising Prevalence of Chronic Diseases Expands Addressable Market Opportunity
    • Growing Adoption of Multimodal Imaging Solutions Throws the Spotlight on Innovation
    • Focus on Drug Discovery and Development Accelerates Market Dynamics
    • Expansion of Contract Research Organizations (CROs) Boosts Market Prospects
    • Increasing Use of Imaging in Oncology Research Propels Market Expansion
    • Adoption of AI and Machine Learning in Image Analysis Drives Market Dynamics
    • Focus on Non-invasive Imaging Techniques Sustains Market Growth
    • Growing Investments in Preclinical Studies for Rare Diseases Expands Market Reach
    • Focus on Improving Image Resolution and Accuracy Enhances Market Opportunities
    • Regulatory Support for Preclinical Research Activities Propels Market Dynamics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Preclinical Imaging (In-VIVO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Preclinical Imaging (In-VIVO) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Preclinical imaging modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Preclinical imaging modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Preclinical imaging modalities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Preclinical imaging reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Preclinical imaging reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Preclinical imaging reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Preclinical Imaging (In-VIVO) Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • JAPAN
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • CHINA
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: China 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • EUROPE
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Preclinical Imaging (In-VIVO) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Preclinical Imaging (In-VIVO) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • FRANCE
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: France 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • GERMANY
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Rest of Europe Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Rest of Europe 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Asia-Pacific Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Asia-Pacific 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 47: Rest of World Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Rest of World Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Rest of World 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030

IV. COMPETITION